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Abstract
Lutein, a fat-soluble carotenoid with antioxidant properties, may have an effect on respiratory health. However, the evidence is inconsistent.
We aimed to cross-sectionally investigate the association between lutein intake and lung function by measuring forced expiratory volume in
1 s (FEV1), forced vital capacity (FVC) and FEV1/FVC% in adults (aged 45–79 years). We included 4402 participants from the Rotterdam Study,
a prospective cohort study in The Netherlands. Lutein intake was assessed using a validated FFQ. Lung function was assessed using spirometry
around the same time point as the dietary assessment. No independent association was found between lutein intake and FEV1 (−12·17 (95% CI
−34·21, 9·87)ml per SD increase in lutein) after adjustment for age, sex, height, cohort effect, ethnicity, education, weight, total daily energy
intake, smoking status, physical activity, and intakes of fatty acids, dietary ﬁbre, alcohol, β-carotene, β-crypotoxanthin, lycopene and
zeaxanthin. There was also no association between lutein and FVC or FEV1/FVC%. However, after stratiﬁcation by smoking status, lutein
intake was signiﬁcantly associated with lower FEV1/FVC% in current smokers (−1·69 (95% CI −2·93, −0·45)% per SD increase of lutein)
independent of other carotenoids. The present study does not support an independent association between lutein intake and lung function in
adults. However, future studies should focus on the potential inverse association between high lutein intake and lung function in speciﬁc risk
groups such as smokers.
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Chronic obstructive pulmonary disease (COPD) is currently
the third cause of death worldwide(1). Interestingly, poor lung
function is an important predictor of mortality in patients with
COPD and in the general population(2–4).
Several studies have focused on evaluating the impact of
nutritional therapy in COPD patients(5); however, it is unclear
how speciﬁc dietary components may inﬂuence lung function(6).
Lutein is a carotenoid without vitamin A capacities, but with
powerful antioxidant capacities(7). The main sources of lutein are
kale, spinach and collards(8). Furthermore, lutein is well known
for its antioxidant effect in the eye, where it protects the retina
from inﬂammation and oxidative stress(7). With this in mind, it
may be the case that lutein has the same protective function in
the lungs; counteracting a retardation in pulmonary function.
It is hypothesised that carotenoids, including lutein, can protect
the airways from inﬂammation-induced damage. Schunemann
et al. reported in both their studies (cross-sectionally and
prospectively) a strong antioxidant effect of lutein (serum and
dietary intake) on lung function(9,10). It has been suggested that
inadequate dietary intake of antioxidants is associated with the
development of respiratory diseases(11,12).
The association between lutein intake and respiratory health
has recently been reviewed(13), and very few studies in adult
populations have been carried out(9,10,14–16). However, these
studies combined lutein with zeaxanthin and did not exten-
sively adjust for confounders or comprised selected populations
(e.g. only in women, young adults or patients with COPD).
To date, there are no recommended levels of intake for lutein;
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RS-I–III, Rotterdam Study
cohorts I–III.
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therefore, from a public health perspective, it is important to
determine whether recommendations are required. We aimed
to cross-sectionally evaluate the effect of lutein intake on lung
function as measured by forced expiratory volume in 1 s (FEV1),
forced vital capacity (FVC) and the FEV1/FVC%, in adults from
a general population (aged 45–79 years), taking into account
socio-demographic, lifestyle and nutritional factors.
Methods
Study design
The present study was conducted with data from the
Rotterdam Study, an ongoing, prospective, population-based
cohort study since 1990, including adults aged 45 years or older
living in the well-deﬁned district Ommoord, a neighbourhood
of Rotterdam, The Netherlands(17). The Rotterdam Study was
approved by the Medical Ethics Committee of the Erasmus
University, and written informed consents were collected
from all participants(17). The original aim of the Rotterdam Study
was to investigate factors related to frequently occurring
diseases in the elderly, as this group is particularly vulnerable
to diseases(17,18). Further information about the objectives
and study design of the Rotterdam Study itself is described
elsewhere(17).
The baseline visit of the ﬁrst Rotterdam Study cohort,
including 7983 participants aged 55 years or older, was
completed between 1990 and 1993 (Rotterdam Study cohort I
(RS-I)-visit 1). From 2000 to 2001, the cohort was extended with
a second cohort of 3011 individuals, who are now 55 years old
or have moved to Ommoord district (RS-II). From 2006 to 2008,
a third cohort of 3932 individuals aged 45–54 years living in
Ommoord (RS-III) was added(17). Participants were invited for
follow-up measurements every 3–4 years.
Study participants
Data from the present study were collected from participants
attending the ﬁfth visit of the original cohort (RS-I-visit 5;
2009–2011; n 2140), the third visit of the second cohort
(RS-II-visit 3; 2011–2012; n 1887) and the second visit of the
third cohort (RS-III-visit 2; 2012–2013; n 3000). We excluded
participants for whom dietary intake data were not available
(n 1337), participants who had an abnormal total energy intake
below 2092 kJ (500 kcal) or above 20 920 kJ (5000 kcal) (n 158)
and participants who did not have an interpretable spirometry
(n 1130). Thus, we included data from 4402 individuals in these
analyses. A ﬂow chart is given in Fig. 1.
Dietary intake of lutein
For RS-I-visit 5 (2009–2011), RS-II-visit 3 (2011–2012) and
RS-III-visit 1 (2006–2008), self-reported dietary intake was
assessed using a FFQ. Participants were asked to ﬁll in a FFQ at
home to report their nutritional intake in the past year. The
FFQ was a comprehensive, 389-item, semi-quantitative ques-
tionnaire based on an existing validated FFQ developed for
Dutch adults(19,20). The FFQ included questions such as the
frequency of consumption of food items over the last month,
the amount and type of food item and preparation methods.
Portion sizes in g/d were estimated using standardised
household measures(21). Dietary data were converted into
nutrient intakes (including daily lutein intake and total energy
intake) using the Dutch Food Composition Tables of 2006
and 2011(22,23).
Lung function
The main outcomes assessed in the present study were the
FEV1, FVC and FEV1/FVC%. Trained personnel measured lung
function using Master Screen® PFT Pro (CareFusion) according
to the American Thoracic Society (ATS)/European Respiratory
Society (ERS) guidelines(24). To ensure reproducibility, multiple
efforts were required. The values of the best acceptable effort
were used for analyses. Spirometry tests that did not meet
ATS/ERS acceptability and reproducibility criteria were classi-
ﬁed as ‘not interpretable’.
Confounders
Before the baseline research centre visit, home interviews were
conducted by trained interviewers. Thereafter, participants
were invited for clinical examination and laboratory tests at
the research centre. At the baseline visit of the original cohort
(RS-I-visit 1 1990–1993), data of multiple factors were collected.
For the present analyses, level of education and ethnicity of the
baseline visit were used as proxies for education and ethnicity
of the ﬁfth visit (RS-I-visit 5; 2009–2011). Level of education was
divided into two groups – low (primary education or less) and
high (levels above primary education). Ethnicity of participants
was based on the ethnic background of the participants’
grandparents, and was divided into Caucasian and non-
Caucasian. Physical activity was measured in metabolic
equivalent task-h per week, which was a combination of
questions on sport, walking, cycling and gardening. Smoking
status was divided into three categories – never smoker, former
smoker and current smoker. Data on the following confounders
used for the analyses were collected from the ﬁfth visit itself
(RS-I-visit 5; 2009–2011): age, sex, height, weight, total daily
energy intake, physical activity and smoking status. In addition,
other potential dietary confounders were collected by the FFQ:
total fat intake, ratio of n-3:n-6 fatty acids (N3:N6), and intakes
of ﬁbre, alcohol, β-carotene, β-cryptoxanthin, lycopene and
zeaxanthin.
At the baseline visit of the second cohort (RS-II-visit 1;
2000–2001), data on education and ethnicity were collected in
the same way as for the baseline visit of the original cohort and
were used as proxies for education and ethnicity of the third
visit (RS-II-visit 3; 2011–2012). Ethnicity was based on the ethnic
background of the participants’ parents, and was divided into
the same categories as the RS-I-visit 1. The other factors were
collected from the third visit itself.
Data on education, ethnicity, physical activity and dietary intake
of the ﬁrst visit of the third cohort (RS-III-visit 1; 2006–2008) were
also collected according to the above-mentioned methods and
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used as proxies for education, ethnicity and dietary intake data of
the second visit (RS-III-visit 2; 2012–2013). The other factors were
collected from the second visit itself.
Statistical analysis
We used linear regression analysis to estimate cross-sectionally
the effect of 1 SD increase in dietary lutein intake (continuous)
on the change in FEV1 (ml), FVC (ml) and FEV1/FVC%. We also
tested the relationship for non-linearity using natural splines
(online Supplementary Fig. S1)(25). There was no evidence for
a non-linear relationship, but as no recommended daily intake
of lutein exists, we decided to categorise dietary lutein intake
into four quartiles. As there is no European reference data for
lutein intake available, the second quartile (1·9–3·2mg) was
chosen as a reference group, as this quartile was in agreement
with the average daily intake of lutein for males (2·0–2·3mg)
and females (1·7–2·0mg) in the USA(26).
Confounders were selected on the basis of published litera-
ture and a 10% change in the effect estimate of the association
between dietary lutein intake and indices of lung function, as
described by Mickey & Greenland(27). Lutein and other dietary
covariates were adjusted for total energy intake, using the
residual method(28). Thereafter, analyses were performed with
adjustment for social-demographic factors (age, sex, height,
cohort, ethnicity and education) in the analyses labelled as
model 1. Model 2 was additionally adjusted for lifestyle factors:
weight, total daily energy intake, total fat intake, N3:N6, ﬁbre
intake, alcohol intake, smoking status and physical activity. To
adjust for other carotenoids, model 3 included additional
adjustment for intakes of β-carotene, β-cryptoxanthin, lycopene
and zeaxanthin. α-Carotene could not be included in this
model because of multicollinearity (the correlation between
α-carotene and β-carotene was 0·96).
We tested for signiﬁcant interactions (P< 0·10) between
lutein and sex, age, BMI (BMI=weight/height2), smoking
status, previous diagnosis of lung cancer, asthma and COPD.
Subgroup analyses were conducted for smoking and BMI, as
a signiﬁcant effect of BMI on lung volume has been demon-
strated(29) in addition to an effect modiﬁcation of smoking on
lung function(30,31). Stratiﬁed analysis was conducted by
smoking status and BMI strata according to the World Health
Organization(32). In addition, the main analyses were repeated
with the exclusion of participants with diabetes and/or CVD.
Seven confounders contained missing values. In general,
missing values were low. The percentages of missing values
ranged from 0·02 (height and weight) to 3·4% (ethnicity).
To account for potential attrition bias, multiple imputation
was used to create ten different possible copies of the original
data set, in which the missing values were substituted by
imputed values (online Supplementary Table S1). These
imputed values were calculated from their predictive distribu-
tion based on the observed data(33). Combined results of the
created data sets (n 10) were then pooled in a separate pooled
data set to account for the uncertainty about the missing
values. An outline of the procedure is described in the online
Supplementary Table S2.
In addition, the main results are presented as effect estimates
and 95% CI for the indices of lung function, and a P value <0·05
was considered statistically signiﬁcant. IBM SPSS Statistics for
Windows (release 21.0.0.1) was used to perform the analyses.
Results
Table 1 details the study population characteristics, subdivided
by cohort. The average age per cohort ranged from 56 to
79 years; women were slightly more represented than men, and
the population was almost exclusively Caucasian. The median
Primary population Rotterdam Study
RS I-5, n 2140
RS II-3, n 1887
RS III-2, n 3000
Population for analysis
RS I-5, n 1133
RS II-3, n 1320
RS III-2, n 1949
Participants with dietary intake data
RS I-5, n 1441
RS II-3, n 1557
RS III-1, n 2692
Excluded: participants with no FFQ
RS I-5, n 699
RS II-3, n 330
RS III-1, n 308
Excluded: participants with unusual energy
  intake data,
RS I-5, n 68
RS II-3, n 42
RS III-1, n 48
Excluded: participants with no FEV1, FVC and
  FEV1/FVC % data
RS I-5, n 240
RS II-3, n 195
RS III-2, n 695
Fig. 1. Flow chart of the participants included in the study (n 4402). RS-I–III-1–5, Rotterdam Study cohorts I–III-visits 1–5; FEV1, forced expiratory volume in 1 s;
FVC, forced vital capacity.
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Table 1. Characteristics of participants in the Rotterdam Study (n 4402)
(Numbers and percentages; mean values and standard deviations; medians and interquartile ranges (IQR))*
RS-I-visit 5 (n 1133) RS-II-visit 3 (n 1320) RS-III-visit 2 (n 1949)
n % n % n %
Age (years)
Mean 79 72 56
SD 4 5 6
Female 638 56·3 731 55·4 1130 58·0
Height (cm)
Mean 166·1 168·3 171·2
SD 9·1 9·1 9·2
Weight (kg)
Mean 75·9 78·0 80·5
SD 13·4 13·6 15·4
Caucasian ethnicity 1107 97·7 1265 95·8 1850 94·9
FEV1 (litre)
Mean 2·22 2·48 2·92
SD 0·65 0·70 0·77
FEV1 (%)
Mean 103·5 101·8 103·6
SD 22·9 20·7 17·7
FVC (litres)
Mean 2·96 3·26 3·82
SD 0·82 0·88 0·99
FEV1/FVC
Median 76·4 77·1 77·5
IQR 71·3, 79·9 72·5, 81·0 73·0, 81·3
Dietary intake
Lutein intake (mg/d)
Median 2·09 2·50 3·18
IQR 1·20, 3·57 1·41, 4·12 1·87, 5·09
Total energy intake (kJ/d)
Median 8096 8234 9301
IQR 6477, 9979 6573, 9920 7724, 11343
Total energy intake (kcal/d)
Median 1935 1968 2223
IQR 1548, 2385 1571, 2371 1846, 2711
α-Carotene intake (mg/d)
Median 0·57 0·61 0·82
IQR 0·23, 1·06 0·25, 1·28 0·36, 1·62
β-Carotene intake (mg/d)
Median 3·10 3·46 4·43
IQR 1·66, 5·19 1·86, 6·15 2·55, 7·38
β-Cryptoxanthin intake (mg/d)
Median 0·30 0·28 0·27
IQR 0·11, 0·68 0·10, 0·56 0·11, 0·50
Lycopene intake (mg/d)
Median 0·95 1·25 1·73
IQR 0·43, 1·89 0·59, 2·38 0·90, 2·92
Zeaxanthin intake (mg/d)
Median 0·13 0·13 0·14
IQR 0·09, 0·18 0·09, 0·18 0·01, 0·18
Total fat intake (g/d)
Median 65·4 68·1 77·9
IQR 50·5, 86·4 51·4, 86·4 60·2, 100·0
N3:N6 (g/d)
Median 6·8 6·8 7·1
IQR 5·9, 7·7 6·0, 7·6 6·3, 7·9
Dietary fibre intake (g/d)
Median 24·1 24·3 28·0
IQR 18·1, 31·5 19·0, 31·1 21·8, 35·8
Physical activity (MET-h/week)
Median 30·0 42·9 46·0
IQR 11·9, 66·9 17·7, 82·3 19·4, 82·1
Smoking status
Never 379 33·3 441 33·4 691 35·5
Former 667 59·0 749 56·7 1000 51·3
Current 87 7·7 130 9·9 258 13·2
Education level
Lower education 575 50·8 647 49·0 817 42·0
Higher education 558 49·2 673 51·0 1132 58·0
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daily lutein intake was 2·09mg/d in RS-I-visit 5, 2·50mg/d in
RS-II-visit 3 and 3·12mg/d in RS-III-visit 1. The median energy
intake was 8101 kJ/d (1935 kcal/d) in RS-I-visit 5, 8240 kJ/d
(1968 kcal/d) in RS-II-visit 3 and 9307 kJ/d (2223 kcal/d) in
RS-III-visit 1. The prevalence of chronic diseases differed
among the three cohorts, where 44, 32 and 27% of the parti-
cipants had diabetes, CVD, COPD, asthma or lung cancer in
cohort RS-I-visit 5, RS-II-visit 3 and RS-III-visit 2, respectively.
Table 2 shows the Spearman’s correlations between the
carotenoids. Correlation of lutein with other carotenoids ranged
from 0·19 (β-cryptoxanthin) to 0·76 (β-carotene).
Lutein intake and lung function
In comparison with the second quartile, the ﬁrst and lowest
quartile of lutein intake was signiﬁcantly associated with both a
lower FEV1 and a lower FVC in the ﬁrst model adjusted for
socio-demographic factors (−53·07 (95% CI −94·14, −12·01)ml,
−49·34 (95% CI −95·42, − 3·25)ml, respectively) (Table 3).
After additional adjustment for lifestyle factors (model 2), the
associations were attenuated, and thus they were no longer
signiﬁcant. No signiﬁcant associations were observed between
the third and the fourth quartiles of lutein intake and FEV1, FVC
and FEV1/FVC%, or for the linear associations between lutein
and FEV1, FVC and FEV1/FVC%. Additional adjustment for
carotenoids (model 3) did not have an effect on these results.
Sensitivity analysis
We did not ﬁnd a signiﬁcant interaction between lutein and sex,
age, lung cancer, asthma or COPD (P value all ≥0·133).
Although we did not observe a signiﬁcant interaction for
smoking with FEV1, FVC or FEV1/FVC% (Pinteraction ≥0·133),
stratiﬁed analyses revealed that lutein was signiﬁcantly associ-
ated with lower FEV1 and FEV1/FVC% in smokers after adjusting
for socio-demographic factors and lifestyle factors (−60·08
(95% CI −115·84, −4·31)ml, −1·64 (95% CI −2·63, −0·65)% per
SD increase in lutein, respectively) (Tables 4 and 6). After
adjustment for other carotenoids, some of the results were
attenuated; however, the association remained signiﬁcant for
lutein and FEV1/FVC (−1·69 (95% CI −2·93, −0·45)% per SD
increase of lutein). As compared with the second quartile, the
fourth and highest quartile of lutein intake was signiﬁcantly
associated with a lower FEV1 and a lower FVC in smokers
(Tables 4 and 5). Moreover, the association remained signiﬁcant
after full adjustment (model 3: −157·55ml fourth quartile v.
second quartile (95% CI −311·32, −3·79)) for FEV1 and attenuated
for FVC. Before adjustment for lifestyle factors, lutein was not
signiﬁcantly associated with FEV1/FVC%, but the association
became signiﬁcant after adjustment (model 2: −2·79% fourth
quartile v. second quartile (95% CI −5·15, −0·41)) (Table 6). After
full adjustment, this association became borderline signiﬁcant.
In addition, we observed similar results after stratiﬁcation by
BMI and exclusion of participants with diabetes and/or CVD
(data not shown).
Discussion
In a population-based prospective cohort study, we investi-
gated the cross-sectional association between dietary lutein
intake and lung function as measured by FEV1. We observed
a weak association between lutein and FEV1 and FVC in
adults aged 45 years and older, after adjustment for socio-
demographic factors. However, this was mainly explained by
other nutrients and lifestyle factors. Strikingly, we found that
lutein intake was associated with lower lung function as
measured by FEV1/FVC% in smokers. To date, there are no
dietary recommendations regarding lutein intake; therefore, it is
important to clarify to what extent lutein may be related to
health outcomes.
Table 1. Continued
RS-I-visit 5 (n 1133) RS-II-visit 3 (n 1320) RS-III-visit 2 (n 1949)
n % n % n %
Type 2 diabetes mellitus 137 12·1 52 3·9 98 5·0
CVD† 67 0·1 67 5·9 63 3·2
Asthma 61 5·4 75 5·7 102 5·2
COPD 224 19·8 211 16·0 266 13·6
Lung cancer 17 1·5 11 0·8 1 0·1
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; N3:N6, n-3:n-6 fatty acids ratio; MET h/week, metabolic equivalent of task-h per week;
COPD, chronic obstructive pulmonary disease.
* Based on imputed data.
† Treatment for narrowed blood vessels, myocardial infarction, stroke, cerebral haemorrhage and cerebrovascular accident.
Table 2. Spearman’s correlations of dietary carotenoids (n 4402)
Lutein α-Carotene β-Carotene β-Cryptoxanthin Lycopene Zeaxanthin
Lutein X 0·55** 0·76** 0·18** 0·19** 0·44**
α-Carotene X 0·96** 0·17** 0·19** 0·34**
β-Carotene X 0·19** 0·23** 0·41**
β-Crypotoxanthin X 0·13** 0·74**
Lycopene X 0·18**
** P≤0·001, a P value <0·05 is considered to be statistical significant.
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Findings in other studies
Our ﬁnding that lutein is not associated with FEV1 and FVC
is in line with a few other observational studies on FEV1
(9,10,15)
and one study on FVC(15). A population-based prospective
study found a signiﬁcant association between lutein/zeaxanthin
and FEV1, FVC and FEV1/FVC%; however, they investigated
the association in adults with chronic airﬂow limitation(14).
A previous longitudinal study found a borderline signiﬁcant
association between lutein/zeaxanthin and a slower decline in
FEV1, and a signiﬁcant association between lutein/zeaxanthin
and FVC. However, this study was conducted in young
adults with a mean age of 25 years(16). A borderline signiﬁcant
association between lutein/zeaxanthin blood levels and FVC
has been described(9), and these authors have also demon-
strated a signiﬁcant association between lutein/zeaxanthin
intake and FVC(10). In addition, all studies that investigated
lutein/zeaxanthin also investigated the association between
other carotenoids and/or antioxidant vitamins and lung
function. Schunemann et al.(9,10) reported that lutein/
zeaxanthin dietary intake and blood levels were strongly related
to lung function, although not signiﬁcant for FEV1, as compared
with other nutrients with antioxidant capacities such as
beta-carotene. This was also reported by Ochs-Balcom et al.(14),
who demonstrated that lutein/zeaxanthin, measured by dietary
intake and blood levels, was strongly related to FEV1, FVC
and FEV1/FVC%. Dietary lutein intake has been examined
by two out of ﬁve studies that investigated lung function in
adults(9,10,14–16). A study found a signiﬁcant positive
association between lutein/zeaxanthin and all indices of
lung function(14). Moreover, a second study found a sig-
niﬁcantly positive association between lutein/zeaxanthin and
FVC only(10).
Interestingly, subgroup analysis by smoking status in
our study revealed that lutein intake was associated with
a lower lung function as measured by FEV1/FVC%. Although
this has not been reported before, other studies have
documented the potential harmful effects of other carotenoids
on lung outcomes. For example, intervention studies suggest
that carotenoid supplementation increased lung cancer and
mortality in heavy smokers(34–38). Indeed, the association
between lutein intake and FEV1 in smokers was explained
by adjustment for other carotenoids, suggesting that the
inverse association between lutein intake and indices of
lung function may be explained to a certain extent by other
carotenoids.
Table 3. Association between dietary lutein intake and forced expiratory volume in 1 s (FEV)1, forced vital capacity (FVC) and FEV1/FVC% (n 4402) –
pooled analysis
(β-Coefficients and 95% confidence intervals)
Model 1† Model 2‡ Model 3§
β 95% CI β 95% CI β 95% CI
FEV1 (ml)
Lutein intake (per SD) 0·84 −13·85, 15·53 −5·92 −23·17, 11·33 −12·17 −34·21, 9·87
P 0·911 0·501 0·279
Lutein intake in quartiles
1st quartile (n 1101) −53·07 −94·14, –12·01* −25·60 −66·11, 14·91 −24·72 −65·51, 16·08
2nd quartile (n 1100) Ref. Ref. Ref.
3th quartile (n 1101) 5·01 −35·95, 45·96 10·31 −29·94, 50·56 9·38 −31·17, 49·94
4th quartile (n 1100) −25·72 −66·90, 15·45 −20·68 −64·18, 22·82 −24·18 −71·65, 23·30
FVC (ml)
Lutein intake (per SD) 1·71 −14·78, 18·19 5·02 −14·41, 24·45 −8·11 −32·92, 16·70
P 0·839 0·613 0·522
Lutein intake in quartiles
1st quartile (n 1101) −49·34 −95·42, –3·25* −26·38 −72·01, 19·24 −22·10 −68·03, 23·83
2nd quartile (n 1100) Ref. Ref. Ref.
3th quartile (n 1101) 4·78 −41·18, 50·75 13·68 −31·65, 59·00 9·39 −36·27, 55·05
4th quartile (n 1100) −27·48 −73·69, 18·72 −10·57 −59·55, 38·41 −28·52 −81·95, 24·91
FEV1/FVC%
Lutein intake (per SD) 0·03 −0·19, 0·25 −0·25 −0·50, 0·01 −0·18 −0·51, 0·15
P 0·788 0·059 0·287
Lutein intake in quartiles
1st quartile (n 1101) −0·45 −1·06, 0·17 −0·12 −0·72, 0·49 −0·17 −0·78, 0·43
2nd quartile (n 1100) Ref. Ref. Ref.
3th quartile (n 1101) 0·06 −0·55, 0·67 −0·02 −0·58, 0·61 0·07 −0·53, 0·68
4th quartile (n 1100) −0·02 −0·64, 0·60 −0·24 −0·88, 0·41 0·02 −0·69, 0·72
Ref., reference values.
* P<0·05.
† Model 1 is adjusted for age, sex, height, ethnicity, cohort and education.
‡ Model 2 is adjusted as for model 1, plus weight, total daily energy intake, total fat intake, n-3:n-6 fatty acids ratio, fibre intake, alcohol intake, smoking status and physical activity
measured in metabolic equivalent of task-h per week.
§ Model 3 was additionally adjusted for daily intakes of β-carotene, β-cryptoxanthin, lycopene and zeaxanthin.
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Mechanisms
The belief that relates lutein intake with improved respiratory
health is based mainly on counteracting oxidative stress.
Antioxidants are known to act against reactive oxygen species
(ROS), which can be divided into exogeneous oxidants
(e.g. cigarette smoke) and endogeneous oxidants (i.e. produced
by inﬂammatory cells)(39,40). Oxidative stress, an imbalance
Table 4. Association between dietary lutein intake and forced expiratory volume in 1 s (FEV1), stratified by smoking status – pooled analysis
(β-Coefficients and 95% confidence intervals)
Model 1† Model 2‡ Model 3§
β 95% CI β 95% CI β 95% CI
Never/former smokers (n 3927), FEV1 (ml)
Lutein intake (per SD) 2·06 −12·94, 17·06 0·03 −15·92, 15·97 −11·69 −34·68, 11·31
P 0·787 0·998 0·319
Lutein intake in quartiles
1st quartile (n 959) −37·23 −79·69, 5·23 −28·09 −70·49, 14·31 −25·93 −68·93, 17·07
2nd quartile (n 998) Ref. Ref. Ref.
3th quartile (n 989) 8·81 −33·20, 50·82 11·20 −30·71,·53·11 9·06 −33·38, 51·50
4th quartile (n 981) −5·34 −47·65, 36·98 −6·06 −49·42, 37·30 −14·25 −63·94, 35·45
Smokers (n 475), FEV1 (ml)
Lutein intake (per SD) −46·29 −97·05, 4·47 −60·08 −115·84, –4·31* −52·38 −124·49, 19·72
P 0·074 0·035 0·154
Lutein intake in quartiles
1st quartile (n 142) −61·79 −190·47, 66·89 −41·19 −171·29, 88·92 −41·87 −173·31, 88·57
2nd quartile (n 102) Ref. Ref. Ref.
3th quartile (n 112) −20·75 −155·10, 113·60 −24·42 −159·77, 110·93 −20·38 −158·22, 117·46
4th quartile (n 119) −166·85 −300·48, –33·21* −178·52 −317·17, –39·88* −157·55 −311·32, –3·79*
Ref., reference values.
* P<0·05 (Pinteraction=0·13).
† Model 1 is adjusted for age, sex, height, ethnicity, cohort and education.
‡ Model 2 is adjusted as for model 1, plus weight, total daily energy intake, total fat intake, n-3:n-6 fatty acids ratio, fibre intake, alcohol intake and physical activity measured in
metabolic equivalent of task-h per week.
§ Model 3 was additionally adjusted for daily intakes of β-carotene, β-cryptoxanthin, lycopene and zeaxanthin.
Table 5. Association between dietary lutein intake and forced vital capacity (FVC), stratified by smoking status – pooled analysis
(β-Coefficients and 95% confidence intervals)
Model 1† Model 2‡ Model 3§
β 95% CI β 95% CI β 95% CI
Never/former smokers (n 3927), FVC (ml)
Lutein intake (per SD) 2·80 −14·43, 20·03 6·18 −14·29, 26·64 −11·75 −38·08, 14·58
P 0·750 0·554 0·382
Lutein intake in quartiles
1st quartile (n 959) −36·91 −85·68, 11·86 −24·61 −73·12, 23·90 −19·21 −68·07, 29·66
2nd quartile (n 998) Ref. Ref. Ref.
3th quartile (n 989) 3·66 −44·59, 51·90 9·47 −38·41, 57·36 4·17 −44·06, 52·40
4th quartile (n 981) −10·21 −58·81, 38·39 −0·85 −52·78, 51·09 −23·58 −80·32, 33·16
Smokers (n 475), FVC (ml)
Lutein intake (per SD) −28·58 −82·14, 24·98 −24·58 −89·27, 40·11 −1·54 −78·43, 75·36
P 0·296 0·456 0·969
Lutein intake in quartiles
1st quartile (n 142) −75·91 −211·54, 59·71 −58·30 −195·07, 78·47 −58·63 −195·96, 78·70
2nd quartile (n 102) Ref. Ref. Ref.
3th quartile (n 112) 17·09 −124·50, 158·68 19·79 −122·60, 162·16 26·57 −117·37, 170·52
4th quartile (n 119) −154·77 −295·62, –13·92* −138·51 −288·90, 11·89¥ −108·90 −270·75, 52·95
Ref., reference values.
Pinteraction=0·549, * P<0·05,
¥ P= 0·071.
† Model 1 is adjusted for age, sex, height, ethnicity, cohort and education.
‡ Model 2 is adjusted as for model 1, plus weight, total daily energy intake, total fat intake, n-3:n-6 fatty acids ratio, fibre intake, alcohol intake and physical activity measured in
metabolic equivalent of task-h per week.
§ Model 3 was additionally adjusted for daily intakes of β-carotene, β-cryptoxanthin, lycopene and zeaxanthin.
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between antioxidant capacity and ROS(41,42), is suggested to
be associated with worsening of lung function. For instance,
an association between increased markers of oxidative stress
(i.e. malondialdehyde or oxidised LDL and decreased lung
function in COPD patients has been found(43,44). However, our
results are not in line with this hypothesis. On the basis of
this mechanism, it can be suggested that the function of lutein
(as an antioxidant) depends on the level of exposure to
smoking (as an oxidant). For that reason, we performed
stratiﬁed analyses by smoking status, as it has been proposed
that a high intake of carotenoids may reduce their protective
function against ROS, particularly in smokers and may
even enhance smoke-induced oxidative stress(45). A possible
explanation for this lost function is that cigarette smoke
modiﬁes the chemical composition of these nutrients, turning
antioxidants into pro-oxidants(46). Hence, further studies on the
potentially harmful effects of dietary lutein intake in smokers
are required.
Methodological considerations
Several important strengths of our study can be acknowledged.
In comparison with previous studies, we have a large
population-based sample size, and were able to adjust for
a wide range of confounders including lifestyle and dietary
factors as well as intakes of other carotenoids, which were
found to be very important.
However, some limitations also need to be taken into
account. First, our study had an observational cross-sectional
design, which prevents ﬁnal conclusions about the causality of
the observed associations. We found that other dietary and
lifestyle factors largely explained the observed association. With
this in mind, it may be important to study overall dietary
patterns in relation to lung function as this takes the inter-
correlation between dietary factors into account(47). Indeed,
several dietary patterns have been found to be associated with
lung function(48–54). Second, we only had information on diet-
ary intake of lutein and not on blood levels. It may be argued
that the blood levels of lutein give a better reﬂection of lutein
status in the human body. For example, when studying blood
levels, unmeasured factors such as genetic factors can be better
taken into account(55). In contrast, when high oxidative stress is
present, such as in COPD, blood levels of antioxidants may
decrease because of an increased demand, which leads to
lower blood levels of antioxidants as a consequence, such as
lutein(56). Hence, reverse causality might be present, as it
remains unknown whether individuals with, for example,
COPD have low blood levels of antioxidants as a consequence
of the disease (e.g. physiologically or due to altered
dietary intake), or whether low blood levels contribute to the
development of the disease. Although our results were not
different after excluding participants with chronic diseases,
reverse causation might still partly explain the ﬁndings. Third,
we used a FFQ for dietary assessment of lutein, which is subject
to measurement error. To account for potential systematic
measurement error, we adjusted lutein intake for total energy
intake(28). However, non-differential misclassiﬁcation may still
be present, which may have led to bias towards the null(57).
Fourth, selection bias or survival bias may be present, as we
selected participants for this study on the basis of available
information on their dietary intakes and lung function.
Table 6. Association between dietary lutein intake and forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC%), stratified by smoking
status – pooled analysis
(β-Coefficients and 95% confidence intervals)
Model 1† Model 2‡ Model 3§
β 95% CI β 95% CI β 95% CI
Never/former smokers (n 3927), FEV1/FVC%
Lutein intake (per SD) 0·04 −0·18, 0·26 −0·14 −0·40, 0·12 −0·08 −0·42, 0·26
P 0·726 0·297 0·646
Lutein intake in quartiles
1st quartile (n 959) −0·26 −0·88, 0·36 −26·0 −0·88, 0·37 −0·31 −0·94, 0·32
2nd quartile (n 998) Ref. Ref. Ref.
3th quartile (n 989) 0·24 −0·37, 0·85 0·18 −0·44, 0·76 0·23 −0·39, 0·85
4th quartile (n 981) 0·20 −0·42, 0·82 −0·02 −0·68, 0·65 −0·22 −0·51, 0·95
Smokers (n 475), FEV1/FVC%
Lutein intake (per SD) −0·63 −1·51, 0·26 −1·64 −2·63, –0·65 −1·69 −2·93, –0·45
P 0·168 0·002 0·008
Lutein intake in quartiles
1st quartile (n 142) −0·22 −2·49, 2·04 0·29 −1·92, 2·51 0·22 −2·01, 2·45
2nd quartile (n 102) Ref. Ref. Ref.
3th quartile (n 112) −1·39 −3·76, 0·98 −1·84 −4·15, 0·46 −1·76 −4·10, 0·58
4th quartile (n 119) −1·39 −3·68, 0·90 −2·79 −5·15, –0·41* −2·57 −3·91, −1·22¥
Ref., reference values.
Pinteraction=0·033, * P< 0·05,
¥ P =0·056.
† Model 1 is adjusted for age, sex, height, ethnicity, cohort and education.
‡ Model 2 is adjusted as for model 1, plus weight, total daily energy intake, total fat intake, n-3:n-6 fatty acids ratio, fibre intake, alcohol intake and physical activity measured in
metabolic equivalent of task-h per week.
§ Model 3 was additionally adjusted for daily intake of β-carotene, β-cryptoxanthin, lycopene and zeaxanthin.
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Individuals with lower lung function or at a severe stage of
chronic disease might not have visited the research centre, and
therefore may have been excluded from the present study. This
exclusion could have underestimated our association. How-
ever, the socio-demographic characteristics (e.g. age, sex,
height, body weight, ethnicity and smoking status) of the
included participants in our study did not differ from the total
population of the Rotterdam Study(58).
In conclusion, we investigated the cross-sectional association
between dietary lutein intake and lung function in a large,
population-based, prospective cohort study. Although we
observed some associations between lutein intake and lung
function, the majority of these disappeared after adjustment
for other nutrients and lifestyle factors. This suggests that
a combination of healthy dietary and lifestyle factors might
contribute to an improved lung function instead of lutein intake
alone. Future studies in the general population should focus on
whole diet to identify patterns in foods linked to speciﬁc
nutrients that are associated with lung function. Interestingly,
we observed that higher lutein intake was associated with a
lower lung function in smokers. This ﬁnding supports previous
evidence on the adverse effect of high intakes of antioxidants in
smokers. However, to date, there is no dietary recommendation
for lutein, which is urgently needed in the clinical setting, as
harmful effects might manifest when a high dose is taken by
particular risk groups. Future studies should also be aware of
the potential inverse association between high lutein intake and
speciﬁc risk groups such as smokers. To date, the effect of high
doses of nutrients that are included in nutritional supplements
for the general population or risk groups is poorly studied.
A trial by Omenn et al.(38) investigated the protective effect of
high doses of vitamin A and β-carotene on lung cancer, which
were discontinued when the incident risk of lung cancer was
shown to be higher in the treatment group as compared with
the control group. Some trials supported their ﬁndings, and
some other research groups did not(59). In addition, some risk
groups might beneﬁt from a nutrition supplement and others
may not(59). For example, (pre) pregnant women are advised to
take folate supplementation to avoid spina biﬁda; however,
a high dose of folate increased the risk of adenomas in a trial
investigating colorectal adenomas(60). These examples demon-
strate that more research is needed to give a public health
recommendation on nutritional supplements.
Supplementary material
For supplementary material/s referred to in this article, please
visit https:/doi.org/10.1017/S0007114517000319
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